Brief: CNS Pharmaceuticals Commences Patient Enrollment In Study Of Berubicin

CNS Pharmaceuticals

19/05/2021 13:06

May 19 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS COMMENCES PATIENT ENROLLMENT IN
POTENTIALLY
PIVOTAL STUDY OF BERUBICIN
    * CNS PHARMACEUTICALS - SUBLICENSEE, WPD PHARMACEUTICALS TO
INITIATE A PHASE 2 MULTICENTER CLINICAL TRIAL IN POLAND OF
BERUBICIN IN GBM IN H2 2021
    * CNS PHARMACEUTICALS INC - INTERIM ANALYSIS OF FIRST 18
ADULT
PATIENTS EXPECTED IN FIRST HALF OF 2022
    * CNS PHARMACEUTICALS INC - INTERIM ANALYSIS OF TRIAL WHEN
50% OF
PLANNED SUBJECTS REACH 6 MONTHS IN STUDY

Source text for Eikon:  ID:nPn5wDDhqa 
Further company coverage:  CNSP.O 

 ((Reuters.Briefs@thomsonreuters.com;))